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Sir,
Shabaruddin et al (2010) recently reported on the results of a
survey conducted by expert UK oncologists regarding their use by
irinotecan for colorectal cancer, with the intent of using these data to
explore the cost-effectiveness of routine UGT1A1 testing. Reading
this article, we were struck with the wide variation in the experts’
answers, and wondered, as did the authors, as to how accurate the
experts might be. To further explore this observation, we put the
same questions to seven Melbourne (Australia) oncologists who
work at four institutions. We then compared these responses with
prospective data that they had collected on 604 patients with
metastatic colorectal cancer, who had presented with stage IV
disease, or developed recurrence, between 2005 and 2009.
We were initially struck by the similarity of the estimates made
by the UK and Melbourne experts (Table 1) regarding treatment
used in the first- to third-line setting. Examining the Melbourne
data, it was evident that the Melbourne experts were over-
estimating the use of irinotecan, with even the lowest estimate of
any expert being higher than real practice. In the third-line setting,
regarding the use of mitomycin C, the discordance between
estimates and real data was most striking (40% estimate versus
17.4% reality). This is consistent with clinicians reporting that they
found it more difficult to estimate treatment use with increasing
lines of therapy.
The Melbourne experts’ estimates for irinotecan duration in the
second-line setting were quite accurate; however, in the first-line
setting, in which all but one expert said either 5 or 6 months, the
real data showed 3.2 months. The estimates of the incidence of
febrile neutropenia ranged from 2 to 8%. Remarkably, the mean
result was 5.4%, which is the exact figure found for the real data.
One possible explanation for the similarity between the UK and
Melbourne estimates, in instances in which there are comparable
data, is that both groups may be basing their answers on a
common set of reference data, such as clinical trial results or other
published data. Experts may then use this knowledge to derive
their estimates, rather than have a true awareness of what is
happening in their practice. To explore this possibility further, we
compared the Melbourne experts’ estimates with available trial
data. The duration of irinotecan use in first-line trials was 5.5–6.5
months (Douillard et al, 2000; Saltz et al, 2000; Tournigand
et al, 2004) and that in second-line studies was
1.5–4.1 months (Cunningham et al, 1998; Tournigand et al,
2004; Sobrero et al, 2009; Gibbs et al, 2010), which was quite
similar to the experts’ estimates (see Table 1). In two studies
enrolling patients in a first-line setting, the percentage who then
received second-line treatment was reported as 54 and 62%
(Tournigand et al, 2004; Seymour et al, 2007), which is again
similar to the experts’ estimates. The reported incidence of febrile
neutropenia ranged from 2.1% (Douillard et al, 2000) to 7.1%
(Sobrero et al, 2009), again in line with the experts’ estimates.
If the above explanation were true, we would also anticipate that
experts’ estimates would be accurate when real data were similar to
trial data, and inaccurate when, for whatever reason, there were
significant differences between clinical studies and real life. This is
most obvious for the duration of use of first-line irinotecan, in
which further analysis of our hospital treatment data revealed that
the dominant use of irinotecan in this setting was when patients
had recently failed oxaliplatin-based adjuvant treatment, a poor
prognosis group. This would explain the duration of first-line
irinotecan treatment being similar to irinotecan use in the second-
line setting, wherein patients typically receive treatment following
failure of first-line oxaliplatin-based therapy. Although in retro-
spect this is an obvious explanation for the abbreviated first-line
irinotecan-based treatment, it appears that only one of our experts
may have factored this into their answers.
Finally, we also suggest that when there were no available trial data
as a reference point, estimates were not only likely to be inaccurate
but there was also a much wider variation in the answers provided by
the experts. An example of such a query would be the use of third-line
mitomycin C, or the reasons for discontinuing irinotecan. When these
a r ee x a m i n e d ,t h ed a t a( T a b l e1 )a p p e a rc o n s i s t e n tw i t ht h i s
observation. Estimates of third-line mitomycin C use ranged from 0
to 80%, and therapy completion as the reason for cessation of therapy
ranged from 10 to 50%; in both instances the means were quite
different from the real data.
It is worth noting that when data are combined, as would be
required for the analysis that Shabaruddin et al were undertaking,
the inaccuracy of the experts’ opinions across the multiple data
sets would be compounded. For example, regarding first-line
irinotecan use, the amount of drug used per 100 patients in the
Melbourne experts’ opinion would be 66 months (5 months
duration in 13.2 patients per 100), a total that is 41.1 months or Published online 9 November 2010
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5.9% of patients). Other estimates would be closer, including
second-line irinotecan use, which parallels clinical trial data;
others would be out by much more, such as the third-line use of
mitomycin C.
Historically, for a speciality so driven by clinical trials that
produce large amounts of data, we would agree with Shabaruddin
et al that the scant amount of data regarding treatment and
outcomes in routine care is surprising. Although collecting data is
achievable, as we have demonstrated (see also http://www.biogrid.
org.au), we acknowledge that it does require significant effort
and resources. However, if understanding what is happening in
routine care is important, and we believe it is for multiple reasons,
then we would suggest that the necessary investments to support
this must be made. On the basis of our small study, using the
estimates of experts appears to be of limited value, and could be
potentially quite misleading. These estimates may also become
increasingly unreliable as treatment paradigms become more
complex, use of biological therapy becomes more widespread and
multiple lines of therapy become more common.
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Table 1 Survey results of seven medical oncologists, compared with real data from patients treated at four hospitals at which they work
Query Melbourne experts mean (range) UK experts mean
a Clinical trial data Melbourne data
First-line treatment
Oxaliplatin based 74.3% (55–90) 72.8% N/A 70.1%
Irinotecan based 13.2% (7–20) 4.5% 5.9%
Second-line treatment
Oxaliplatin based 15.1% (10–20) 17.7% 25.9%
Irinotecan based 69.8% (60–80) 63.7% 54–62% 54.2%
Third-line treatment
Mitomycin C 40% (0–80) 50% N/A 17.4%
Duration
First-line irinotecan 5.0months (3–6) 5months
b 5.5–6.5months 3.2months
Second-line irinotecan 3.3months (2–4) 1.5–2.0months 3.5months
Ceasing irinotecan
Therapy completion 26.5% (10–50) 25%
c N/A 40.3%
Disease progression 51.4% (40–70) 62% 39.6%
Treatment toxicity 15.26% (10–25) 32% 12.2%
Patient request 6.8% (0–15) — 3.6%
Febrile neutropenia 5.4% (2–8) 8.4% 2.1–7.1% 5.4%
Abbreviation: N/A¼not applicable.
aAll oxaliplatin and irinotecan regimens combined.
bNot broken down by first- and second-line treatment.
cNumbers in survey do not add
to 100%.
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